Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plainview whey recalls continue

This article was originally published in The Tan Sheet

Executive Summary

Additional firms recall whey protein supplements potentially contaminated with salmonella from Plainview Milk Products Cooperative, including certain batches of SNI Pro Whey from Nutrition Global and Weigh Down Chocolate Flavor Nutrition Drink Mix from Lewis Laboratories International. A spokeswoman for GNC said in an e-mail the retailer's private label whey products are unaffected, but firms recalled four third-party stock-keeping units carried in the stores. Despite the range of firms and products affected by the recalls, Plainview acted quickly and no illnesses are reported linked to its ingredients (1"The Tan Sheet" July 13, 2009)

You may also be interested in...



Whey Recall Grows, But Plainview Approach May Prevent A Peanut Replay

The recall of whey protein ingredients rippling its way through the dietary supplement industry shows that companies must take a risk-based approach to product safety and cannot rely on good manufacturing practices alone to protect them

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS103165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel